{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-066724","form_type":"8-K","ticker":"RYTM","cik":"0001649904","company_name":"RHYTHM PHARMACEUTICALS, INC.","filed_at":"2025-07-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.561852+00:00","generated_at":"2026-05-18T08:53:40.783492+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rhythm Pharma's bivamelagon Phase 2 meets endpoints: -9.3% BMI reduction at 14 weeks","bullets":["BMI reduction -9.3% (600mg, p=0.0004) and -7.7% (400mg, p=0.0002) vs 2.2% increase on placebo.","Mean reduction >2.8 points in 'most' hunger score on 10-point scale in 600mg and 400mg cohorts.","Safety consistent with MC4R agonism; one discontinuation due to serious AE (rectal bleeding).","Rhythm plans End-of-Phase 2 meeting with FDA and EU scientific advice for registrational path.","Data from 26 of 27 patients continued into open-label extension as of July 7, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-066724","json":"https://secwatch.observer/filing/0001104659-25-066724.json","markdown":"https://secwatch.observer/filing/0001104659-25-066724.md","text":"https://secwatch.observer/filing/0001104659-25-066724.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649904/000110465925066724/0001104659-25-066724-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649904/000110465925066724/tm2520203d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T08:53:40.783492+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}